Notably, the rules include guidance on ultraviolet A (UVA) rays, the type of ray linked to skin cancer and early skin aging.
FDA last week released new rules for oil, cream, and lotion sunscreen products. Notably, the rules include guidance on ultraviolet A (UVA) rays, the type of ray linked to skin cancer and early skin aging. Prior sunscreen rules only addressed ultraviolet B (UVB) rays and their sunburn effects.
In order to better inform consumers about which sunscreens offer greatest protection from both UVA and UVB rays, the rule states:
The rules take effect by next summer, but the agency notes that sunscreen companies may begin making labeling changes before then.
In addition, FDA is seeking public feedback, in the form of Advance Notice of Proposed Rulemaking, for other forms of sunscreen-containing products, including sunscreen sprays, powders, towelettes, body washes, and shampoos.
In response to the news, the Personal Care Products Council noted: “We are also pleased that FDA reaffirmed there are no safety issues with any of the sunscreen active ingredients, including nanoscale titanium dioxide and zinc oxide.”
However, it also noted “…we are concerned about manufacturers’ ability to make the required testing and labeling changes in only 12 months given the thousands of products on the market, the limited number of testing facilities, and the time needed to redesign product labeling. It is unusual for FDA to require such a short implementation period for a rulemaking of this scope. Manufacturers typically require at least two years to design and implement broad-scale, product-wide labeling changes.”
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.